Sanofi reported higher earnings and sales for the first quarter, mainly thanks to Dupixent and consumer healthcare, and said it expects further growth in earnings per share activity during 2022.
The French pharmaceutical company announced a net profit of 2 billion euros for the quarter, higher than 1.57 billion euros a year ago.
Sales stood at 9.67 billion euros, up from 8.59 billion euros a year ago.
Net business profits stood at 2.42 billion euros from 2.02 billion euros a year ago.
Business profits per share amounted to 1.94 euros, higher by 20.5% compared to the corresponding quarter of the previous year.
For 2022, Sanofi expects business earnings per share to grow at a low double-digit rate at a fixed exchange rate, with a positive impact of between 4% -5%.
Source: Capital
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
